A dynamic combinatorial library (DCL) screening approach is described that permits direct identification of the effective (from ineffective) combination of building blocks in the equilibrating DCL. The approach uses Fourier transform ion cyclotron resonance mass spectrometry (FTICR MS) together with sustained off-resonance irradiation collision activated dissociation (SORI-CAD) to detect noncovalent protein-DCL ligand complexes under native conditions. It was shown that in a single, rapid experiment one could concurrently identify all the ligands of interest from the DCL against a background of inactive DCL ligands while still in the presence of the target protein. This result has demonstrated that mass spectrometry may provide a fast preliminary screening approach to identify DCL candidates for later verification with more traditional but time-consuming analysis.
Introduction
Dynamic combinatorial chemistry (DCC) has added a new dimension to the synthetic capability of combinatorial chemistry by allowing the combinatorial synthesis to occur through reversible covalent reactions [1] [2] [3] . The benefit of this additional dimension becomes readily evident when dynamic combinatorial libraries (DCLs) are prepared in the presence of a therapeutic target molecule. The reversible chemistry, together with the target acting as a template, permits selfscreening owing to selection and amplification of the 'best binders' by molecular recognition events between DCL constituents and the target. There are now multiple examples of ligand discovery from dynamic combinatorial libraries (DCLs) generated in the presence of protein targets [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . In principle DCC has the potential to circumvent the need to individually synthesize, characterize and screen each possible library constituent, however rapid detection of the enriched DCL product(s) still poses a serious analytical problem and is a critical limitation to DCC taking a prominent place in drug discovery [21] . The standard DCL screening approach must carry out the screening of identical DCLs twice -with and without the target -and then compare the equilibrium concentration profiles of all library ligands when generated in both the absence and presence (following disruption of the ligand-target complexes) of target protein [4, 7, 10, [14] [15] [16] [17] -the detection of ligand enrichment in the targeted DCL is the basis of identifying the 'best binders'.
Unfortunately this screening approach typically necessitates the need for synthesis of individual library components to validate chromatographic (eg. HPLC) or spectral (eg. NMR) assignments, this is both labour and time-intensive and has the effect of undermining the promoted advantages of DCC. The complexity of screening with this indirect method also increases with the size of the DCL owing to chromatographic and/or spectral overlap so that the preparation and screening of DCL sub-libraries becomes necessary for deconvolution of larger DCLs. For DCC to have a significant impact on drug discovery will necessitate the development of a direct screening protocol(s) for rapid identification and characterization of those ligands with affinity for the target protein, against the background of inactive DCL constituents. It would be a tremendous advantage to drug discovery applications of DCC if DCL screening methodologies could proceed without the need for chromatography, prior conversion to a static library, preparation of sub-libraries, prior disruption of the protein-ligand complexes, synthesis of individual library ligands to validate spectral assignments or for the preparation and duplicate screening of identical DCLs (with and without the target).
The analytical demands of combinatorially generated compound libraries has directed the attention of the pharmaceutical industry towards mass spectrometry owing to attributes of speed, intrinsic sensitivity, specificity, low sample consumption and capability of resolving vast numbers of compounds in complex compound mixtures [22] . The application of mass spectrometry for studying noncovalent native interactions between proteins and ligands is also well established and the optimization of experimental parameters to reflect solution composition (and minimize nonspecific complexes) has been described [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . On this basis it was postulated that integration of DCL synthesis with a mass spectrometry based screen could fulfil the screening requirements alluded to above and so provide an alternative means for identifying the most effective combination of building blocks in a DCL with a given target.
The target selected for the current study was the enzyme carbonic anhydrase (CA) (EC 4.2.1.1).
Modulation of CAs has been exploited clinically for several decades, however more recently a role for CA inhibition as an anticancer therapy has been identified owing to a predominance of some CA isoforms in cancer cells and has again created interest in this enzyme as a therapeutic target [36, 37] . Hydrazone exchange is now one of the most promising reversible reactions for DCC drug discovery applications [5, 6, 13, 19] as it may be performed under reaction conditions that do not disrupt the target proteins function or structure [38, 39] and was the reversible reaction implemented here to generate DCLs targeting CA (Scheme 1). This paper describes the application of electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry (ESI FTICR MS) to the direct screening of a DCL generated by hydrazone exchange against the protein target bovine carbonic anhydrase II (bCA II). The technique combines the attributes of ESI MS described above and in addition exploits the capabilities of the FTICR technique to selectively trap, then dissociate these protein-ligand complexes to facilitate DCL ligand identification [25, 26, 30] . 
Experimental

DCL Building Block Design
Building block 1, a benzene sulfonamide hydrazide, was synthesized as the scaffold building block from which to generate a DCL. Dual functionality was incorporated into the design of 1 to provide a scaffold with both reliable bCA II affinity (aromatic sulfonamide) and the capacity to take part in acyl hydrazone exchange (hydrazide moiety). An aromatic sulfonamide moiety (ArSO 2 NH 2 ) is the primary recognition element for small molecules to bind the active site of CA [40, 41] .
Benzhydrazide (2) lacks the sulfonamide moiety of 1, but is still able to participate in hydrazone exchange. Control compound 2 was incorporated into the DCL as a means of generating compounds expected to have no affinity for the target bCA II. Five additional building blocks A-E (each containing an aldehyde to act as the hydrazone exchange partners of 1 and 2) were also synthesized. Building blocks A-E were derived from amino acids and were selected to introduce 'tails' onto 1 to enable exploration of periphery recognition interactions with bCA II that may complement the primary bCA II interaction with the aromatic sulfonamide moiety. performed on E. Merck Silica gel GF-60 grade silica (particle size 0.0400 -0.063 mm). Analytical thin-layer chromatography was performed on 0.25 E Merck silica-gel plates (60-F-254). Analysis of TLC was conducted using standard short-wave UV, KMnO 4 and ninhydrin stains, as appropriate.
A-E
Reaction yields less than < 1 g were purified with Varian TM mega bond elut solid-phase extraction columns (normal phase silica). Building block 1 was synthesized from 4-carboxybenzene sulfonamide [42] . Aldehyde building blocks A-E were synthesized in two steps from commercially available amino acid methyl esters. Workup involved washing with water (10 mL), 2M Na 2 CO 3 (10 mL) and water (10 mL). The final organic fraction was dried over MgSO 4 , the solvent removed and the crude material purified by solid-phase extraction on normal-phase silica sorbent using CH 2 Cl 2 and EtOAc as eluant. The pure chromatography fractions were combined and the solvent removed to afford the amide products as white solids. 
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Mass Spectrometry
The mass spectrometry presented in this paper was performed on an APEX® III 4.7 Tesla FTICR mass spectrometer (Bruker Daltonics, Billerica, MA, USA) fitted with an Apollo™ ESI source operated in negative ion mode. XMASS NT V7.0.2 mass spectrometry software on a PC platform was used for data acquisition. Broadband excitation was used to analyze a mass range from m/z 100 -4500, with 256K, 128 K or 32 K data points acquired. Samples were infused into the ESI source at 2 μLmin -1 . Nitrogen was used as both the drying gas (125 ºC) and nebulizing gas. Relevant parameters include the ESI source pressure (6.2x10 -7 mbar), high vacuum analyser region pressure (1.3x10 -10 mbar) and hexapole accumulation time of 1 s. MS/MS experiments were performed by sustained off-resonance irradiation collision activated dissociation (SORI-CAD) using argon as the collision gas at an analyzer pressure of ~10 -8 mbar (argon inlet pressure 2.9x10 -2 mbar). The parent ions were selected by use of correlated sweep isolation. The CAD collision energy was tuned to cause dissociation of the noncovalent protein-ligand complexes. Agilent ES tuning mix (catalogue number G2421A) was used for an external four-point calibration. 
Generation of Dynamic Combinatorial Libraries
Results and Discussion
Confirmation of Reversibility of Hydrazone Exchange
Aqueous ammonium acetate is a 'volatile buffer' suitable for ESI MS applications to study native protein-ligand noncovalent complexes. This buffer (pH 7.2) has not before been used for hydrazone exchange and so preliminary for this study was confirmation that hydrazone exchange was indeed dynamic under the conditions as used for subsequent MS investigations (hydrazone exchange is rapid at acidic pH). Solutions (i) to (iv), each containing a unique hydrazide/aldehyde combination, were prepared in 10 mM NH 4 OAc, 1% DMSO (pH 7.2) and incubated at 37 ºC for 40 h. The formation of expected hydrazone products was confirmed by negative ion ESI MS (Table 1) . Less than 5% free hydrazide or aldehyde was detectable.
Solutions (i) and (ii) were then combined (Mix 1 = 1B, 2E) as were solutions (iii) and (iv) (Mix 2 = 1E, 2B) and incubated (without agitation) at 37 ºC (Scheme 3). The hydrazone composition of both mixes was monitored over time by ESI FTICR MS analysis (Figure 1) . Initially only the original hydrazones were present in solution (Figure 1, entry a) , but over time the rearranged hydrazones 1E and 2B appeared in Mix 1 and rearranged hydrazones 1B and 2E appeared in Mix 2 (Figure 1,   entries b-d) . This experiment confirmed that hydrazone exchange was reversible under the neutral conditions used for the native ESI FTICR MS screening. 
Screening of DCLs Using Mass Spectrometry
ESI FTICR MS analysis of bCA II in aqueous ammonium acetate yielded the ESI negative ion mass spectrum of Figure 2 , entry a. Peaks corresponding to the 8 -to 10 -charge states of bCA II were observed, with the 9 -charge state predominating. This charge state envelope (low charge states and few charge states) is typical for bCA II when in a compact, tightly folded native structure [25] [26] [27] .
The mass spectrum of the DCL prepared from 1, 2 and A-E in the presence of bCA II (conditions (i) of Scheme 2) is presented in Figure 2 (Table 2) . No ions in the MS/MS spectrum could be attributed to hydrazones 2A-2E (lacking the sulfonamide moiety). As only hydrazides (1 and 2) and aldehydes (A-E) were incubated with the target protein the hydrazones identified from the DCL with affinity for bCA II must have been synthesized in situ by DCC. These results demonstrate that the MS screening approach was able to directly identify ligands of interest from a DCL whilst in the presence of the target protein without the need for any prior workup. 
Validation of Mass Spectrometry Screening Results by a Conventional Enzyme Assay
A conventional solution phase competitive binding assay [43] [44] [45] for bCA II was used to measure the equilibrium dissociation constants (Ki's) for the compounds described in this study. The fluorescence-based assay relies on the competition for the active site of bCAII between the ligand 5-(dimethylamino)-1-napthalenesulphonamide (DNSA) and the test compound [45] . Upon excitation at 290 nm (an absorption minimum for DNSA) fluorescence is detected at 460 nm (from the bCAII-DNSA complex). Each of the DCL hydrazones 1A-1E, 2A-2E as well as building blocks 1 and 2, and aldehydes A-E were individually assessed for their ability to inhibit the binding of DNSA to the active site of bCA II. As expected 2, 2A-2E and aldehydes A-E (each lacking the sulfonamide moiety) showed no competitive inhibition of DNSA binding even at ligand concentrations up to 100 μM. The equilibrium dissociation constants (Ki's) measured for sulfonamides 1 and 1A-1E are given in Table 3 . The DCL products 1A-1E each exhibited increased affinity for the enzyme (Ki range 10.6 -82.3 nM) when compared to the scaffold building block 1 (Ki = 150 nM). These conventional assay results were in complete agreement with bCA II ligand affinity as determined in the mass spectral screen as only those ligands with affinity for bCA II (i.e. 
Conclusions
In conclusion, a single and rapid (minutes) mass spectrometry experiment has permitted concurrent identification of all ligands of interest from a DCL in the presence of the protein target, without the need for any prior workup. This direct approach integrates DCL synthesis with screening and offers an attractive single analysis alternative to the current ligand enrichment screening methodology.
The approach readily distinguishes the effective (from ineffective) combination of building blocks in the DCL by detection of specific protein-ligand noncovalent complexes. Comparison with a conventional enzyme assay was fully consistent with the MS result. It is reasonable to expect that increased DCL size need not increase the complexity of this screening protocol, owing to the sensitivity, high resolution and MS/MS capabilities of the FTICR MS technique, this should avoid the need for multiple sub-libraries to deconvolute larger DCLs. This mass spectrometry screening approach may provide a fast preliminary DCL screen to identify candidates for later verification with more traditional but time-consuming approaches as so may better equip DCC for the screening challenges and demands of modern drug discovery programs.
